In Vivo Gene Therapy For Heart Failure
A novel approach to increase the function of a failing heart The use of adenovirus vectors enable easy application of gene therapy in clinical settings The strategy can be used in combination with recommended treatments
Scientists at UCSD and San Diego VA Healthcare System have discovered methods and compositions for increasing function of the failing heart by a one-time intracoronary infusion of an adenovirus vector encoding human AC VI. Salutary effects on the failing heart include increased contractile performance, reduced heart block, normalization of action potential duration, regression of adverse LV remodeling and reduced mortality. These effects have been demonstrated in preclinical animal models. This technology can therefore be used in the treatment of heart disease, especially congestive heart failure.
Patent Number: US6306830B1
Application Number: US19988097A
Inventor: Hammond, H. Kirk | Insel, Paul A. | Ping, Peipei | Post, Steven R. | Gao, Meihua
Priority Date: 5 Sep 1996
Priority Number: US6306830B1
Application Date: 16 Jan 1998
Publication Date: 23 Oct 2001
IPC Current: C12N000988 | A61K004800
US Class: 514044A | 514044 | 4240932 | 4352351 | 4353201
Assignee Applicant: The Regents of the University of California
Title: Gene therapy for congestive heart failure
Usefulness: Gene therapy for congestive heart failure
Summary: USE (I) can be used to form a filtered adenovirus particle preparation. (I) is used to enhance cardiac function in mammals.
Novelty: Vectors containing transgene(s) encoding beta-adrenergic signalling proteins useful for gene therapy of congestive heart failure
Biomedical
DNA/Gene Engineering
6306830
Additional Technologies by these Inventors Tech ID/UC Case 22727/1998-B28-0 Related Cases 1998-B28-0
USA
